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and Motoichi Kurisawa
(-)-Epigallocatechin-3-gallate (EGCG) is a green tea polyphenol that has several biological activities, including anti-cancer and 
anti-inflammation. Hyaluronic acid (HA) is a naturally-occurring polysaccharide widely used as a biomaterial for drug delivery 
and tissue engineering due to its viscoelastic, biocompatible and biodegradable properties. By conjugating HA with EGCG, 
the resulting HA-EGCG conjugate is expected to exhibit not only the inherent properties of HA but also the bioactivities of 
EGCG. Toward this end, we report the synthesis of an amine-functionalized EGCG as an intermediate compound for 
conjugation to HA. EGCG was reacted with 2,2-diethoxyethylamine (DA) under acidic conditions, forming ethylamine-
bridged EGCG dimers. The EGCG dimers comprised of four isomers which were characterized by HPLC, high-resolution mass 
spectrometry and NMR spectroscopy. The amine-functionalized EGCG dimers were conjugated to hyaluronic acid (HA) 
through the formation of amide bonds. HA-EGCG conjugates demonstrated several bioactivities which were not present in 
unmodified HA, including resistance to hyaluronidase-mediated degradation, inhibition of cell growth and scavenging of 
radicals. The potential applications of HA-EGCG conjugates are discussed.  
Introduction 
Tea (Camellia sinensis) is a beverage that is consumed 
worldwide. There are three types of tea, namely black tea, 
oolong tea and green tea. Green tea differs from the others in 
that the tea leaves do not undergo fermentation, or oxidation, 
but are steamed to inactivate the oxidative enzymes after 
harvest.1, 2 Accumulated evidences over the past few decades 
strongly support the potential health benefits of green tea, 
particularly its anti-cancer activity.3-5 Several epidemiological 
studies have revealed an inverse relationship between green 
tea consumption and cancer incidence.2, 6 Moreover, topical 
application of green tea extracts has been shown to be effective 
in treating genital warts caused by human papilloma virus 
(HPV), a non-malignant squamous tumor.7 In addition to its anti-
cancer activity, studies have reported that green tea exhibits 
anti-bacterial and anti-inflammatory properties, as well as 
reducing the risk of cardiovascular diseases and obesity.6  
 The health benefits of green tea have been attributed to 
catechins; in particular, (-)-epigallocatechin-3-gallate (EGCG, 1, 
Scheme 1), the most abundant catechin contained in green tea 
(more than 50% by mass of the total catechin content).8 The 
mechanism through which EGCG exerts its health benefits is 
complex. However, research has revealed several key 
mechanisms of action, particularly with regards to its anti-
cancer activity, including anti-oxidant and pro-oxidative 
properties, inhibition of enzymatic activities, and modulation of 
signal-transduction pathways through interactions with cell 
surface receptors or other molecular targets.4, 5 Despite the 
growing interests in EGCG as a therapeutic agent, the potentials 
of polymer-EGCG conjugates for biomedical applications 
remained underexplored. Polymer-drug conjugates are known 
to enhance the therapeutic efficacy of small molecule drugs by 
improving their solubility and stability, and increasing plasma 
half-life when administered intravenously.9 Furthermore, the 
drugs can be more precisely delivered to the diseased site by 
conjugation to a polymeric carrier containing active targeting 
moieties. To date, only chitosan-EGCG conjugates have been 
reported, which were synthesized by either tyrosinase-
mediated10 or free radical-induced grafting11 of EGCG via the B 
ring.  
 It is known that the B and D rings of EGCG are crucial for its 
bioactivities such as enzyme inhibition,12 induction of 
apoptosis13 and scavenging of radicals.14, 15 For instance, 
decreasing the number of hydroxyl groups in the B ring reduced 
its anti-cancer activity as a proteasome inhibitor.16 Therefore, it 
is desirable to maintain the structure of B and D rings in order 
to preserve the bioactivity of EGCG. From this perspective, our 
group has previously reported a EGCG-terminated 
poly(ethylene glycol) synthesized via an aldehyde-mediated 
reaction that selectively reacts with the C-6 and C-8 positions of 
the A ring.17 In this study, we introduced amine functional 
group, in the form of ethylamine, to the A ring of EGCG using 
the same aldehyde-mediated reaction, forming ethylamine-
bridged EGCG dimers (Scheme 1). The amine-functionalized 
EGCG dimers are useful intermediate compounds which can be 
synthesized in gram-scale for conjugation to polymers. 
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 We demonstrated the conjugation of amine-functionalized 
EGCG dimers to hyaluronic acid (HA) using conventional 
carbodiimide-mediated coupling chemistry. HA is a non-
sulfated glycosaminoglycan found in the extracellular matrix 
(ECM). It exists as high molecular weight polymers under 
normal physiological conditions (106-107 Da), forming a 
viscoelastic mesh that is capable of retaining water and thereby 
maintaining tissue volume.18 HA is the major constituent in the 
vitreous humor and synovial fluid, and is used in various 
medical19, 20 and cosmetic applications. For instance, HA is used 
as a viscoelastic material in ophthalmological surgery to prevent 
the anterior chamber from collapsing and to protect the corneal 
endothelium from damage.21 Intra-articular injections of HA 
provides lubrication and restores viscoelasticity in arthritic 
joints.22 More recently, the interactions between HA and the 
cell surface receptors, such as CD44 and HA receptor for 
endocytosis (HARE), have been explored to achieve targeted 
drug delivery.23 By conjugating EGCG to HA, the resulting HA-
EGCG conjugate is expected to exhibit not only the inherent 
properties of HA but also the bioactivities of EGCG. Indeed, it 
was shown that HA-EGCG conjugates inhibited the enzymatic 
activity of hyaluronidase, decreased the growth rate of cells, 
and scavenged radicals more effectively compared with HA.   
Results and discussion 
Synthesis and characterization of ethylamine-bridged EGCG 
dimers 
The bioactivity of EGCG is attributed mainly to the trihydroxyl 
groups in the B and D rings,12-15 hence it is important to keep 
these sites intact during chemical modifications. Toward this 
goal, we utilized an aldehyde-mediated condensation reaction 
which selectively reacts with the A ring of EGCG.17 The reaction, 
also known as Baeyer acid-catalyzed condensation, occurs 
during wine-aging in which flavanols react with aldehydes to 
form dimeric or oligomeric compounds.24-26 The resulting 
chemical bridge between the flavanols depends on the 
aldehyde that is used for the reaction. In this study 2,2-
diethoxyethylamine (DA), a protected aldehyde, was chosen to 
react with EGCG because it contains a primary amine which can 
form amide bond with the carboxyl groups of HA. Under acidic 
conditions the diethylacetal exists in equilibrium with aldehyde, 
which in turn accepts nucleophilic attack by the C-6 or C-8 of 
EGCG. The resulting intermediate further involves another 
EGCG to elaborate the EGCG dimers 2, 3a, 3b, and 4 (Scheme 
1). 
 It was reported that the aldehyde-mediated condensation 
reaction of flavanols would yield four isomers with 8-8, 6-6 and 
two 6-8 linkages, which stems from the linkage between the 
two reactive sites on the A ring (C-6 and C-8) and the 
asymmetric carbon.25, 26 Indeed, four major peaks were 
observed in HPLC analysis in which two peaks in the middle 
overlapped with each other (Fig. 1). According to the previous 
studies the aldehyde-mediated condensation reaction was 
regioselective due to the sterically favorable substitution of C-8 
over C-6, hence the 8-8 isomer should be generated the most 
while the 6-6 isomer the least.25, 27 Based on this information, 
the largest peak observed in the HPLC, i.e., the first eluted peak, 
was assigned to 2, the 8-8 isomer. The next two overlapping 
peaks accounted for 3a and 3b, the two 6-8 stereoisomers. The 
last eluted peak, which was also the smallest in area, came from 
4, the 6-6 isomer. Each isomer was isolated by preparative HPLC 
for NMR analysis to elucidate the chemical structures. Only 
three fractions were collected because the two overlapping 
peaks, which contained 3a and 3b (6-8 stereoisomers), were 
Scheme 1. Synthesis of ethylamine-bridged EGCG dimers 
Fig. 1 HPLC chromatogram (UV absorbance at 280 nm) of ethylamine-bridged EGCG 
dimers. Arrows indicate the major peaks which correspond to the four isomers.  
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eluted together as one fraction. All three fractions had m/z of 
958 as determined by LC/MS, which corresponded to [M + H]+.  
1H NMR spectrum of the first eluted fraction, which 
contained 2 (8-8 isomer), revealed that the chemical shifts were 
paired, i.e., two peaks with equal intensity, particularly for H-2' 
and H-6' of the B ring and H-2'' and H-6'' of the D ring (Fig. 2a). 
Similarly, several of the 13C chemical shifts were paired (Table 
1). These results imply the presence of two sets of EGCG with 
different resonance, which was likely caused by the formation 
of an ethylamine bridge between two EGCG molecules. The 
broad peak centered at 3.89 ppm was assigned to the CH2 
protons of the ethylamine bridge. The assignment was 
supported by the chemical shift of the corresponding carbon 
determined by 1H-13C HSQC (Fig. S1, ESI†), which was negative 
(43.74 ppm, Fig. 2b), indicating either a secondary, as in this 
case, or a quaternary carbon. A triplet centered at 5.49 ppm was 
found to overlap with the chemical shifts of the H-3 proton of 
EGCG (Fig. 2a inset). This was assigned to the CH proton of the 
ethylamine linkage as coupling of the CH proton to the CH2 
protons of the ethylamine bridge would result in a triplet. 
Indeed, integration from 5.4 to 5.6 ppm revealed the presence 
of three protons, which corresponded to one CH proton and 
two H-3 protons. The chemical shift of the CH carbon as located 
by 1H-13C HSQC (Fig. S1a, ESI†) was positive (31.10 ppm, Fig. 2b), 
indicating either a primary or a tertiary carbon. The CH carbon 
is a tertiary carbon. The unambiguous assignment of the 
resonance of CH2 and CH confirmed the formation of an 
ethylamine bridge between two EGCG molecules. Correlations 
between the protons of CH2 and CH of the ethylamine bridge 
and C8 carbon of EGCG were observed (Fig. S1b, ESI†). 
 In order to assign the six carbon peaks of C-5, C-7 and C-8a 
which resonate closely between 154 to 156 ppm (Fig. 2b, inset), 
1H-13C HMBC focusing on this region was performed to obtain a 
high resolution spectrum. The HMBC correlations were shown 
Fig. 2  NMR spectra of 2 (8-8 isomer): (a) 1H spectrum, the CH protons were buried within the resonance of H-3 as indicated by arrows (inset); (b) 13C spectrum; (c) 1H-13C HMBC 
correlations; (d) 1H-13C HMBC spectrum. 
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in Fig. 2c and the six carbons peaks were assigned as follows. 
The carbons at 154.30 and 154.62 ppm, which showed 
correlations with the CH proton of the ethylamine bridge but 
not the H-6 protons of the A ring, were assigned as C-8a (Fig. 
2d). On the contrary, the carbons at 155.38 and 155.61 ppm, 
which correlated with the H-6 protons but not with the CH 
proton of the ethylamine bridge, were assigned as C-5. The 
remaining two carbons at 155.51 and 155.92 ppm, which 
exhibited correlations with both the CH proton and the H-6 
protons, were assigned as C-7. Similar procedure was applied to 
assign the 1H and 13C peaks for the other isomers (Table 1). 
However, we could not assign the 13C resonance for C-5, C-7 and 
C-8a of 3a and 3b as they were eluted together in one fraction. 
It is worth mentioning that the 1H NMR spectrum of the fraction 
containing 3a and 3b showed four peaks for each of the protons 
of the B ring and D ring (Fig. S2a, ESI†). On the other hand, 1H 
NMR of 4 showed a single peak for each of the protons of the B 
and D rings (Fig. S2b, ESI†).  
Synthesis and characterization of HA-EGCG conjugates 
Ethylamine-bridged EGCG dimers were conjugated to HA by a 
typical carbodiimide-mediated coupling reaction to obtain HA-
EGCG conjugate (Scheme 2). Removal of unreacted EGCG 
dimers from reaction mixture by dialysis against water was 
Scheme 2. Synthesis of HA-EGCG conjugates.  
Table 1 1H and 13C assignments of 2, 3a, 3b and 4 in DMF-d7 (δ in ppm, J in Hz) 
No. 
2 (8-8 isomer) 3a, 3b (6-8 isomers) 4 (6-6 isomer) 
1H 13C 1H 13C 1H 13C 
CH2 3.89 43.73 Burieda 42.80, 43.57 3.90 42.15 
CH 5.45-5.52 31.10 5.35-5.45, 
5.50-5.60 
30.73, 30.96 5.19 (t, J = 7.5) 31.10 
2 5.08, 5.09 78.05 5.00-5.20 77.60, 78.10 5.0-5.1 77.77 
3 5.40-5.55 68.57, 68.80 5.47 68.66, 68.82, 69.09, 
69.21 
5.48 69.06 
4 2.80-3.20 26.31, 26.66 2.80-3.20 26.29, 26.90 2.80-3.20 26.89 
4a - 98.58 - 99.33, 99.38, 99.69, 
100.08 
- 100.98 
5 - 155.38, 155.61 - N.A.c - 154.82, 154.88 
6 6.21, 6.24 96.62, 96.90 6.25, 6.28b 107.95b - 107.20, 107.37 
7 - 155.51, 155.92 - N.A.c - 154.11 
8 - 106.04 6.18, 6.21b 104.74, 105.26b 6.24, 6.25 96.21, 96.38 
8a - 154.30, 154.62 - N.A.c - 155.28, 155.33 
1’ - 129.46, 129.55 - 129.28, 129.58, 
129.63, 129.31 
- 129.36 





3’, 5’ - 146.44 - 146.36, 146.38, 
146.43 
- 146.46 
4’ - 133.14, 133.28 - 133.15, 133.21 - 133.27, 133.29 
0” - 166.08, 166.16 - 165.98, 166.01, 
166.06 
- 166.02, 166.06 
1” - 120.61, 120.64 - 120.52, 120.57 - 120.45 
2”, 6” 7.06, 7.09 109.50, 109.56 7.00, 7.03, 7.06, 
7.09 
109.31, 109.49 7.03 109.31 
3”, 5” - 146.10 - 146.07, 146.12 - 146.17 
4” - 139.14 - 139.10 - 139.14 
aBuried in the H2O peak. b Values may be switched. c Unable to assign accurately because there are two stereoisomers in the sample. 
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attempted but found to be inefficient. Dialysis against a mixture 
of DMF:H2O (10:90, v/v) could remove the unreacted EGCG 
dimers, however the process took several days. On the contrary, 
by precipitating the HA-EGCG conjugates with ethanol in the 
presence of NaCl, HA-EGCG conjugates formed slurry 
precipitates which could be easily collected by centrifugation. 
The unreacted EGCG dimers remained in the supernatant and 
were decanted. After lyophilization the purified HA-EGCG 
conjugate was dissolved in D2O and analyzed by 1H NMR (Fig. 
3a). Although the peaks corresponding to the protons of the B 
and D rings could be observed (Fig. 3a inset), the signal to noise 
ratio of these peaks was too low for accurate integration. Hence 
absorbance measurement was employed to determine the 
degree of substitution. HA-EGCG conjugate showed a peak at 
around 273 nm (Fig. 3b, solid line), which corresponds to the π-
π* transitions of the aromatic rings of EGCG. Ethylamine-
bridged EGCG dimers also showed a peak at 273 nm (dashed 
line) while HA did not (dotted line).  The degree of substitution 
(DS, the number of EGCG dimers conjugated for every 100 
disaccharide units) was calculated by comparing the 
absorbance at 273 nm to a set of EGCG standards. The DS of HA-
EGCG conjugates made from 90 kDa and 800 kDa of HA were 
0.8 and 1, respectively.  
Hyaluronidase inhibition by HA-EGCG conjugates 
Tea polyphenols are known to bind to proteins through 
hydrophobic interaction and hydrogen bonding, thereby 
inhibiting the activity of enzymes.28, 29 Mammalian 
hyaluronidase cleaves the β-1,4-glycosidic bonds of HA, 
generating HA fragments with N-acetyl-D-glucosamine reducing 
ends.30 It is expected that the EGCG moieties of HA-EGCG 
conjugates would inhibit hyaluronidase and reduce the rate of 
enzymatic degradation of the HA backbone. HA-EGCG 
conjugates and HA (2 mg mL-1) were incubated with 
hyaluronidase solution for 20 h and the amount of reducing 
ends and the dynamic viscosity  (η) of the degraded samples 
were measured. In the case of HA-EGCG conjugates, the 
reducing end concentration remained below 0.1 mM as the 
concentration of hyaluronidase increased from 0 to 12.5 U ml-1 
(Figure 4a). On the contrary, the reducing ends increased to 
more than 0.7 mM in the case of HA. Moreover, the dynamic 
viscosities of HA-EGCG conjugates were higher than HA after 
incubation with hyaluronidase (Figure 4b). The results 
suggested that HA-EGCG conjugates are less susceptable to 
degradation by hyaluronidase compared with HA, likely due the 
inhibition of hyaluronidase activity by the EGCG moieties.  
 Chemical modification of HA is known to disrupt 
hyaluronidase binding which in turn hinders degradation by the 
enzyme and can potentially prolong HA residence time in vivo.31 
In one study, the resistance to enzymatic degradation of serine-
grafted HA increased as the degree of substitution increased 
from 40 to 100.32 Extensive modification of HA, however, would 
lead to changes in its physical and biological properties. In 
Fig. 4 Inhibition of hyaluronidase activity. (a) Concentration of reducing end generated 
and (b) dynamic viscosity (η) of HA or HA-EGCG conjugates (2 mg mL-1) after 
treatment with hyaluronidase for 20 h at 37 °C (n = 3, mean ± s.d.).  *P < 0.05 and **P 
< 0.005. 
Fig. 3 Characterization of HA-EGCG conjugates (800 kDa). (a) 1H NMR of 10 mg mL-1 of 
HA-EGCG conjugates in D2O. Chemical shifts of H-2’ and H-6’ of B ring and H-2’’ and H-
6’’ of D ring of EGCG were visible (inset). (b) Absorbance spectra of ethylamine-
bridged EGCG dimer (dashed line, 10 μg mL-1), HA-EGCG conjugate (solid line, 0.5 mg 
mL-1) and unmodified HA (dotted line, 0.5 mg mL-1) in H2O. 
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comparison, only 1% of the carboxyl groups of HA were 
substituted with EGCG dimers in the HA-EGCG conjugate, hence 
it was unlikely that the observed resistance to enzymatic 
degradation was caused by modification of HA. Rather it was 
the interaction between the EGCG moieties and hyaluronidase 
that inactivated the enzyme.  
Anti-proliferative activity of HA-EGCG conjugates 
EGCG is well-known for its anti-proliferative property. We 
examined the anti-proliferative property of HA-EGCG 
conjugates using an in vitro model of rheumatoid arthritis. 
Rheumatoid arthritis is an autoimmune joint disease 
characterized by hyperplasia of the synovial lining, which 
behaves like a local tumor that invades the cartilage and 
underlying bone, leading to joint destruction.33 Human 
fibroblast-like synoviocytes (HFLS) derived from rheumatoid 
arthritis patient were treated with HA, HA-EGCG conjugates or 
EGCG while under stimulation by TNFα to simulate the 
inflammatory environment in vivo. After 3 days incubation, cells 
treated with HA retained healthy morphology across all the 
concentrations (Fig. 5a). Cells treated with HA-EGCG conjugates 
displayed normal morphology; with exception at the highest 
concentration of HA-EGCG conjugates, i.e., 2.5 mg mL-1 
(containing 100 µM of EGCG). At this concentration, cells lost 
their elongated morphology but remained attached to the well. 
Cells treated with EGCG appeared apoptotic at EGCG 
concentrations above 50 µM. The cell number, measured in 
terms of the amount of DNA and expressed as a percentage of 
the control (no treatment), of samples treated with HA was 
similar to the control across the different concentrations (Fig. 
5b). In contrast, DNA amount decreased with increasing 
concentrations of HA-EGCG conjugates or EGCG, suggesting the 
inhibition of cell growth (Fig. 5c). Remarkably, HA-EGCG 
conjugates inhibited cell growth as effectively as EGCG. The 
observed growth inhibition is in agreement with a previous 
study which reported that EGCG can downregulate 
uncontrolled growth and induce apoptosis in HFLS.34 
Radical scavenging activity of HA-EGCG conjugate 
HA is known to have antioxidant activity, which is attributed to 
reactive oxygen species (ROS)-induced chain depolymerization 
and the formation of a viscous meshwork that restricts ROS 
movement.35, 36 However, only high molecular weight HA (3000-
6000 kDa) showed significant radical scavenging activity and 
little effect was observed for low molecular weight HA.35 
Indeed, we found that HA (800 kDa) showed negligible 
scavenging activities towards •NO, •OH and •O2− (Fig. S3, ESI†). 
On the other hand, HA-EGCG conjugates showed concentration-
dependent radical scavenging activities (Fig. S3, ESI†). The 
concentrations at which 50% of the radicals were scavenged 
(SC50) were listed in Table 2. The radical scavenging activity of 
HA-EGCG conjugates was attributed to the EGCG moieties. 
EGCG is one of the most potent radical scavengers among the 
different green tea catechins due to the high number of 
hydroxyl groups contained in the B ring and the galloyl moiety 
(D ring).14, 37 In addition to direct scavenging of radicals, EGCG 
can inhibit the generation of •OH radicals by chelating metal 





HA-EGCG conjugatea 32.3 ± 3.8 36.3 ± 4.3 20.4 ± 3.8 
EGCG 30.4 ± 1.4 18.0 ± 0.5 5.7 ± 1.3 
a Concentration of HA-EGCG conjugates was expressed in terms of the amount of 
EGCG contained in the conjugates 
Fig. 5. HFLS were treated with HA, HA-EGCG conjugates or EGCG for 3 days. (a) 
Representative microscope images of the treated cells. Scale bar = 50 µm. (b-c) 
Amount of DNA, expressed in terms of percentage of the control (no treatment), for 
samples treated with (b) HA, (c) HA-EGCG conjugates or EGCG. HA-EGCG conjugates at 
0.2, 0.3, 0.6, 1.3 and 2.5 mg mL-1 contained 6.3, 12.5, 25, 50 and 100 μM of EGCG, 
respectively (n = 4, mean ± s.d.). 
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ions and preventing them from participating in Fenton 
reaction.38 EGCG can also bind to enzymes such as xanthine 
oxidase (XO) and inhibit its enzymatic activity, which in turn 
prevents the generation of •O2 −.39  
 Hyaff®-11p75 (benzyl esters of HA with an approximate 
molecular weight of 300 kDa), a commercially available HA-
derived product used in wound healing applications, was shown 
to scavenge •O2− more effectively than high molecular weight 
HA (3000-6000 kDa) despite having a lower molecular weight.35 
The superior scavenging activity is attributed to the high degree 
of benzyl groups which offer alternative sites for •O2− attack. 
Though Hyaff®-11p75 can scavenge •O2− effectively, its physio-
chemical property is quite different from that of native HA 
because 75% of the carboxyl groups are esterified with benzyl 
alcohol.  As a result, Hyaff®-11p75 requires DMSO to be 
dissolved due to its high hydrophobicity.35 In contrast, HA-EGCG 
conjugates could not only scavenge •O2− but also remain soluble 
in water. Furthermore, HA-EGCG conjugates could scavenge 
•OH whereas Hyaff®-11p75 was incapable of doing so.
 ROS and reactive nitrogen species are implicated in the 
pathogenesis and progression of various diseases, including 
osteoarthritis and rheumatoid arthritis. For instance, the 
presence of nitrotyrosine in osteoarthritis cartilages and the 
elevation of nitrated type II collagen peptides in the sera of 
osteoarthritis patients suggest oxidative damage caused by the 
highly reactive peroxynitrite (ONOO−), which is a derivative of 
•O2− and •NO.40, 41 Intra-articular injection of HA, also known as
viscosupplementation, is a treatment mode that aims to 
alleviate pain in osteoarthritis patients through restoration of 
HA concentration in the synovial fluid. As HA-EGCG conjugate 
could inhibit HFLS proliferation and scavenge radicals, it is a 
potential candidate for arthritis treatment. Moreover, EGCG 
has been shown to inhibit interleukin-1β (IL-1β)-induced gene 
and protein expressions of metalloproteinases (MMPs) in 
human chondrocytes, including MMP-1 and MMP-13.42 
Elevated levels of MMP-13 in the joint can lead to increased 
cleavage of collagen type II in the cartilage, resulting in cartilage 
destruction. Therefore the EGCG moieties in HA-EGCG 




TEAVIGOTM green tea extract (EGCG, 1, minimum 90%) was 
purchased from DMS Nutritional Products Ltd. (Switzerland). 
Hyaluronic acid (HA, 90 kDa and 800 kDa) was kindly donated 
by JNC Corporation (Tokyo, Japan). Methanesulfonic acid 
(MSA), 2,2-diethoxyethylamine (DA), N-hydroxysuccinimide 
(NHS), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
hydrochloride (EDC⋅HCl), xanthine, sodium nitroprusside, Greiss 
reagent, nitrotetrazolium blue chloride (NBT), thiobarbituric 
acid, 2-deoxy-D-ribose, ascorbic acid, hydrogen peroxide 
(H2O2), trichloroacetic acid and hyaluronidase from bovine 
testes (439 U mg-1) were all purchased from Sigma-Aldrich 
(Singapore). 2-(N-Morpholino)ethanesulfonic acid (MES), iron 
(II) sulfate heptahydrate (FeSO4·7H2O) and N-acetyl-D-
glucosamine were obtained from Merck (Singapore).  Xanthine 
oxidase (XO, 0.34 U mg-1) from buttermilk was purchased from 
Oriental Yeast Co., Ltd. (Japan). p-Dimethylaminobenzaldehyde 
(DMAB) was purchased from Wako Pure Chemical Industries 
(Japan). N,N-Dimethylfomamide-d7 (DMF-d7) was purchased 
from Cambridge Isotope Laboratories, Inc (USA). Human 
fibroblast-like synoviocytes (HFLS) derived from rheumatoid 
arthritis patient were obtained from Cell Applications, Inc. 
(USA). Fetal bovine serum (FBS), penicillin-streptomycin and 
PicoGreen® dsDNA quantitation assay kit were purchased from 
Life Technologies (Singapore). Phosphate buffer saline (PBS, pH 
7.3) and RPMI 1640 were supplied by media preparation facility 
in Biopolis (Singapore). MilliQ H2O was used in all experiments. 
Synthesis of ethylamine-bridged EGCG dimers 
In a glass vial containing 1.2 mL of cold MSA:THF (1:5, v/v) 
mixture, 145 µL of DA (1.0 mmol) was added while stirring. The 
mixture was transferred dropwise to EGCG (2.29 g, 5 mmol), 
which was dissolved in 3.8 mL of THF and 1.7 µL of MSA, and 
stirred overnight in the dark at ambient temperature. The 
resulting mixture was concentrated under reduced pressure 
and further dried under vacuum overnight at ambient 
temperature. The products were dissolved in 10 mL of H2O and 
the unreacted EGCG were removed by extraction with 10 mL of 
ethyl acetate using a separatory funnel. Unreacted EGCG moved 
to the organic layer while the ethylamine-bridged EGCG dimers 
remained in the aqueous layer. The extraction was repeated 
until no free EGCG was detected in the aqueous layer using a 
Waters Acquity UPLC-MS system. The concentration of the 
purified ethylamine-bridged EGCG dimer in the aqueous phase 
was determined by absorbance at 273 nm and was found to be 
84 mg mL-1 (yield = 88%). HRMS-ESI calcd for C46H40NO22 [M + 
H]+ 958.2036, found 958.2062. The dimers were stored at -80 
°C. 
High-performance liquid chromatography (HPLC) 
HPLC was performed by Waters 2695 Separation Module 
equipped with a Waters 2996 Photodiode Array Detector. A 
Spirit HPLC C18 column (5 μm, 25 × 0.46 cm; AAPPTec) was used. 
The mobile phase consisted of H2O and acetonitrile with 1% 
acetic acid. Sample concentration was 5 mg mL-1 and elution 
was carried out at 1 mL min-1 flow rate, 23 °C, with a linear 
gradient of acetonitrile from 10 to 35% in 30 min.   
Nuclear magnetic resonance (NMR) 
The purified EGCG dimers, which contained different isomers, 
were separated by a Gilson preparative HPLC system equipped 
with a Gilson UV/VIS-156 detector. A C18 reversed phase 
preparative column (21.2 mm x 250 mm, Kromasil®) was used. 
The mobile phase consisted of H2O and acetonitrile with 0.1% 
trifluoroacetic acid. Samples were eluted at 15 mL min-1, 25 °C, 
with 10% acetonitrile for 3 min and then gradient to 60% over 
40 min. For NMR analysis, 10 mg of sample from each fraction 
was dissolved in 0.7 mL of DMF-d7 and transferred to a Wilmad 
J-Young low pressure/vacuum NMR tube. Oxygen in the sample 
was removed by three cycles of freeze-pump-thaw. NMR 
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experiments were performed with a Bruker Avance II (400 MHz) 
NMR equipped with a 5 mm PABBO probe. A series of NMR 
experiments were performed for each compound, including 1D 
1H and 13C APT spectra as well as 2D 1H-13C HSQC and HMBC 
spectra using standard pulse programs. All chemical shifts are 
given in ppm values relative to DMF-d7 (1H: δ 2.75 ppm; 13C: δ 
34.89). 
Synthesis of HA-EGCG conjugates 
Ethylamine-bridged EGCG dimers were conjugated to HA by a 
typical carbodiimide-mediated coupling reaction.43 HA (250 mg, 
0.62 mmol) was dissolved by stirring in 20.2 mL of 0.4 M MES 
buffer (pH 5.2) with 2.5 mL of DMF. Next, NHS (89 mg, 0.78 
mmol) and ethylamine-bridged dimers (0.205 mmol in 2.33 mL 
of H2O) were added to the reaction mixture. Then, EDC⋅HCl (150 
mg, 0.78 mmol) was added and the pH of the reaction was 
adjusted to 4.7. The reaction mixture was purged vigorously 
with N2 for 10 min and then incubated in the dark overnight 
under N2 at ambient temperature. The HA-EGCG conjugates 
were purified by precipitation using a previously established 
method with some modifications.43, 44 Briefly, 125 mL of H2O 
and 16.7 mL of 5 M NaCl solution were added to the reaction 
mixture and the pH was lowered to 3 with HCl solution. Then, 
310 mL of ethanol was added while stirring. Under these 
conditions the HA-EGCG conjugates formed slurry precipitates 
which were collected by centrifugation (6000 rcf, 5 min). After 
decanting the supernatant, the precipitates were re-dissolved 
in 250 mL of water. Then, 33 mL of 5 M NaCl solution was added, 
the pH was adjusted to 3, and 620 mL of ethanol was added. 
The precipitates were collected by centrifugation and re-
dissolved in 500 mL of H2O. After adding 67 mL of 5 M NaCl 
solution and lowering the pH to 3, 1.24 L of ethanol was added. 
The precipitates were again collected by centrifugation and re-
dissolved in 300 mL of H2O. The conjugates were then dialyzed 
(Spectra/Por 7, MWCO = 3500 Da) against H2O in N2 
atmosphere overnight. Finally, the purified HA-EGCG 
conjugates were lyophilized. The yield was 185 mg (74%). For 
NMR analysis, the lyophilized conjugates were dissolved in D2O 
at 10 mg mL-1. To determine the degree of substitution (DS, the 
number of EGCG dimers conjugated for every 100 disaccharide 
units), the conjugates were dissolved at 0.5 mg mL-1 in water 
and UV-Vis spectrum was recorded with a Hitachi U-2810 
spectrometer. The amount of EGCG contained in the conjugate 
was determined by comparing the absorbance at 273 nm with 
a set of EGCG standards. HA-EGCG conjugates made from 800 
kDa HA were used for hyaluronidase inhibition and radical 
scavenging assays. HA-EGCG conjugates made from 90 kDa HA 
were filtered through a 0.2 µm syringe filter before 
lyophilization; the lyophilized products were dissolved in sterile 
H2O at 50 mg mL-1 and used for cell growth experiments.  
Hyaluronidase inhibition study 
HA and HA-EGCG conjugates (2 mg mL-1) were treated with 0, 
2.5 and 12.5 U mL-1 of hyaluronidase in 0.1 M sodium phosphate 
buffer (pH 5.7) for 20 h at 37 °C. The amount of reducing ends 
generated was determined by Morgan-Elson assay.45 DMAB 
stock solution was prepared by dissolving 5 g of DMAB in 6.25 
mL of 10 M HCl and then topped up to 50 mL with acetic acid. 
The DMAB reagent was diluted 10-fold with acetic acid 
immediately before use. The hyaluronidase-treated samples 
were first diluted 4-fold with H2O, then 32 µL of which was 
mixed with 8 µL of borate solution (0.741 g of boric acid and 
0.297 g of potassium hydroxide in 15 mL of H2O, pH 9). The 
mixture was heated at 99 °C for 5 min. After cooling down to 
room temperature, 160 µL of DMAB was added and the mixture 
was then incubated at 37 °C for 20 min. 150 µL of the solution 
was transferred to a 96-well plate and the absorbance at 585 
nm was determined by a Tecan Infinite 200 microplate reader. 
The amount of reducing ends was determined by comparing to 
a set of N-acetyl-D-glucosamine standards. The dynamic 
viscosity was measured using a HAAKE Rheoscope 1 rheometer 
equipped with a cone sensor (3.5 cm in diameter and 1.029° 
cone angle) at a shear rate of 400 s-1 and 25 °C. 
Cell culture 
Human fibroblast-like synoviocytes (HFLS) were grown in RPMI 
1640 medium supplemented with 10% FBS and 1% penicillin-
streptomycin. The cells were cultured in T75 tissue culture 
flasks and incubated at 37 °C and with 5% CO2. Cells below 
passage 10 were used. 
Cell growth assay 
To determine the effect of HA, HA-EGCG conjugates and EGCG 
on cell growth, 2.5 x 103 HFLS in 100 µL of complete growth 
medium were seeded on the wells of a 96-well plate. After 
overnight incubation, the spent medium was replaced with 50 
µL of fresh complete growth medium containing 40 ng mL-1 of 
tumor necrosis factor alpha (TNFα). Next, 50 µL of HA, HA-EGCG 
conjugates or EGCG was added. HA/HA-EGCG conjugates and 
EGCG were first dissolved in water at 50 mg mL-1 and 2 mM, 
respectively, before they were diluted in RPMI 1640 and added 
to the wells. The final concentration of TNFα in the wells was 20 
ng mL-1. The final concentrations of HA or HA-EGCG conjugates 
were 0.2, 0.3, 0.6, 1.3 or 2.5 mg mL-1. The final concentrations 
of EGCG were 6.3, 12.5, 25, 50 or 100 μM, which corresponded 
to the concentrations of EGCG contained in the HA-EGCG 
conjugates. The plate was incubated at 37 °C for 3 days, after 
which images of the cells were taken using a microscope, and 
the number of cells in the wells were determined by DNA 
quantification using PicoGreen® dsDNA assay kit. Briefly, the 
spent medium was removed and the cells were lysed with 20 µL 
of 0.2% Triton X-100 in PBS for 30 min on a shaker. Then 180 µL 
of PicoGreen® reagent, prepared according the manufacturer’s 
protocol, was added to each well. The plate was placed for 5 
min in the dark and then the fluorescence was measured using 
a microplate reader (λex = 480 nm and λem = 520 nm). The 
amount of DNA in each well was expressed in terms of the 
percentage of the controls (no treatment). 
Radical scavenging assays 
•NO was generated by sodium nitroprusside and measured
according to a previously described method.46 Briefly, 50 µL of 
HA, HA-EGCG conjugates or EGCG dissolved in H2O at various 
concentrations was added to the wells of a 96-well plate. Then, 
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50 µL of sodium nitroprusside (10 mM in 0.2 M sodium 
phosphate buffer, pH 7.4) was added. After incubation at room 
temperature for 2.5 h under light, 100 µL of Greiss reagent was 
added. After 2 min incubation, the absorbance at 570 nm was 
recorded using a microplate reader. A reaction without any test 
sample (H2O only) was performed as control. The percentage of 
•NO scavenged were calculated using the following equation,
where Acontrol and Asample were the absorbance values of the 
control and sample, respectively: Radicals scavenged (%)= �Acontrol - Asample
Acontrol
�       (1) 
•OH was generated by Fenton reaction using FeSO4 and
H2O2. The amount of •OH was determined by the thiobarbituric 
acid reaction in which the •OH degrades 2-deoxy-D-ribose into 
a 3-carbon compound, malondialdehyde, which then forms a 
chromogen in the presence of thiobarbituric acid.47, 48 100 µL of 
HA or HA-EGCG conjugates dissolved in H2O at various 
concentrations was added to microcentrifuge tubes. Then, a 
solution containing 2-deoxy-D-ribose (20 mM), ascorbic acid (80 
µM) and FeSO4 (80 µM) in 50 µL of buffer (0.2 M sodium 
phosphate buffer with 0.3 M NaCl, pH 7.4) was added. Next, 50 
µL of H2O2 (882 µM) prepared in buffer was added to initiate 
Fenton reaction. After incubating at 37 °C for 1.5 h, 50 µL of the 
reaction mixture was mixed with 50 µL each of trichloroacetic 
acid (2.8%, w/v) and thiobarbituric acid (1% in 50 mM NaOH, 
w/v).  The mixture was heated at 99 °C for 15 min. After cooling 
down to room temperature, 100 µL was transferred to the wells 
of a 96-well plate and the absorbance at 532 nm was measured 
using a microplate reader. The percentage of •OH scavenged 
was determined by equation (1). 
•O2− was generated by XO and xanthine and measured by
NBT reduction assay based on a previously established protocol 
with some modifications.49 Stock solution of xanthine was 
prepared at 2.28 mg mL-1 in 1 M NaOH and diluted 10-fold in 0.2 
M sodium phosphate buffer (pH 7.4) immediately before use. 
50 µL of HA or HA-EGCG conjugates dissolved in H2O was added 
to the wells of a 96-well plate. Then, 15 µL of XO (0.27 units mL-
1), 15 µL of NBT (0.2 mM) and 20 µL of xanthine (1.5 mM), all 
prepared in 0.2 M sodium phosphate buffer (pH 7.4), were 
added sequentially. Production of •O2− was monitored by the 
formation of formazan dye at 560 nm using a microplate reader. 
Absorbance measurement was started immediately after 
adding xanthine and was recorded for 2 min during which the 
absorbance of the control (no test sample) increased linearly, 
suggesting a linear production of •O2−. The slope of the 
absorbance measurement during the 2 min period was 
determined by linear-fitting the data points using Microsoft 
Excel. The percentage of •O2− scavenged was then determined 
by the following equation, where Scontrol and Ssample were the 
slopes of the control and sample, respectively: 
•O2- scavenged (%)= �Scontrol - SsampleScontrol �      (2) 
 The radical scavenging activities were expressed as 50% 
scavenging concentration (SC50), which was the sample 
concentration required to decrease in the signal intensity (•NO 
and •OH) or the slope (•O2−) by 50% relative to the control. 
Statistics 
Results were expressed as the mean ± standard deviation (s.d.). 
The difference between the values was assessed using 
Student’s t-test in Microsoft Excel. 
Conclusions 
Ethylamine-bridged EGCG dimers were synthesized via 
aldehyde-mediated reaction with the A ring of EGCG. Four 
isomers were formed due to the two reactive sites on the A ring, 
i.e., C-6 and C-8, and the asymmetric carbon at the ethylamine 
linkage. The EGCG dimers were conjugated to HA using 
carbodiimide-mediated coupling reaction, forming HA-EGCG 
conjugates. We demonstrated that the resulting HA-EGCG 
conjugates possess bioactivities such as resistance to 
hyaluronidase-mediated degradation, inhibition of cell growth 
and scavenging of radicals, whereas unmodified HA showed no 
or limited activities. The HA-EGCG conjugate would be a 
promising material for biomedical applications, such as arthritis 
treatment.  
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